Maintenance Rituximab or Observation after Frontline Treatment with Bendamustine-Rituximab for Follicular Lymphoma

Bendamustine (B) with rituximab (R) is a standard frontline treatment for medically fit follicular lymphoma (FL) patients. The safety and efficacy of maintenance rituximab (MR) after BR induction has not been formally compared to observation for FL, resulting in disparate practice patterns. Prospect...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Br J Haematol
Asıl Yazarlar: Hill, Brian T., Nastoupil, Loretta, Winter, Allison M., Becnel, Melody R., Cerhan, James R., Habermann, Thomas M., Link, Brian K., Maurer, Matthew J., Fakhri, Bita, Reddy, Prathima, Smith, Stephen D., Mukhija, Dhruvika, Jagadeesh, Deepa, Desai, Amrita, Alderuccio, Juan Pablo, Lossos, Izidore S., Mehra, Pooja, Portell, Craig A., Goldman, Max L., Calzada, Oscar, Cohen, Jonathon B., Hussain, Mohammad Junaid, Ghosh, Nilanjan, Caimi, Paolo, Tiutan, Timothy, Martin, Peter, Kodali, Abhigna, Evens, Andrew M., Kahl, Brad S.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2018
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6486816/
https://ncbi.nlm.nih.gov/pubmed/30575016
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bjh.15720
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller